|
|
|
|
LEADER |
02002nam a22002895i 4500 |
001 |
978-1-59259-083-4 |
005 |
20190617201214.0 |
007 |
cr nn 008mamaa |
008 |
100301s2000 xxu| s |||| 0|eng d |
020 |
|
|
|a 9781592590834
|
024 |
7 |
|
|a 10.1385/1592590837
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Vaccine Adjuvants
|b Preparation Methods and Research Protocols /
|c edited by Derek T. O’Hagan.
|
250 |
|
|
|a 1st ed. 2000.
|
260 |
# |
# |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2000.
|
300 |
|
|
|a X, 342 p.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Methods in Molecular Medicine,
|v 42
|
505 |
0 |
|
|a An Overview of Adjuvant Use -- Harmful and Beneficial Activities of Immunological Adjuvants -- Freund's Adjuvants -- Aluminum Compounds as Vaccine Adjuvants -- Poly(Lactide-Coglycolide) Microparticles As Vaccine Adjuvants -- Poly(Methyl Methacrylate) Nanoparticles As Vaccine Adjuvants -- Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers -- Liposomes As Immunological Adjuvants and Vaccine Carriers -- Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) -- Cochleates for Induction of Mucosal and Systemic Immune Responses -- Virus-like Particles As Vaccine Adjuvants -- The Adjuvant MF59: A 10-Year Perspective Gary Ott, Ramachandran Radhakrishnan, -- Preparation of the Syntex Adjuvant Formulation (SAF, SAF-m, and SAF-1) -- The ISCOM™ Technology -- QS-21 Adjuvant -- MPL® Immunostimulant: Adjuvant Formulations -- Cytokines As Vaccine Adjuvants: The Use of Interleukin-2 -- DNA As an Adjuvant -- Transcutaneous Immunization -- Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction.
|
650 |
|
0 |
|a Immunology.
|
650 |
1 |
4 |
|a Immunology.
|
700 |
1 |
|
|a O’Hagan, Derek T.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
856 |
4 |
0 |
|u https://doi.org/10.1385/1592590837
|